| P2093 | author name string | Christoph Luger | |
| | Andreas Maieron | |
| | Helmut Mittermayer | |
| | Sigrid Metz-Gercek | |
| | Franz Hackl | |
| | Rainer Schöfl | |
| | Alexander Ziachehabi | |
| | Harri Fuchsteiner | |
| P2860 | cites work | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 |
| | Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 |
| | Diagnosis, management, and treatment of hepatitis C | Q29620656 |
| | Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia | Q33373442 |
| | Patients with chronic heart failure encountered in daily clinical practice are different from the "typical" patient enrolled in therapeutic trials | Q35133933 |
| | Treatment Considerations in Patients With Hepatitis C and Cirrhosis | Q35562000 |
| | Hepatitis C genotype 4: What we know and what we don't yet know. | Q37073708 |
| | Efficacy of chronic hepatitis C therapy in community-based trials | Q37485031 |
| | Disappointing results of combination therapy for HCV? | Q42836223 |
| | A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. | Q42978180 |
| | Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. | Q42985188 |
| | Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response | Q42992693 |
| | Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection | Q42997055 |
| | Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin | Q42999474 |
| | Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. | Q43001787 |
| | Short-term treatment duration for HCV-2 and HCV-3 infected patients | Q43030675 |
| | HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin | Q43032582 |
| | Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study | Q43036320 |
| | Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin | Q43036338 |
| | Staphylococcus aureus bacteremia in patients receiving pegylated interferon-alpha and ribavirin for chronic hepatitis C virus infection | Q43039479 |
| | Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Q43040369 |
| | Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. | Q43040978 |
| | Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response | Q43041800 |
| | Evaluating the effectiveness of asthma treatment in real-life practice | Q44930783 |
| | Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome | Q45212087 |
| | Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection | Q45396908 |
| | Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice | Q47669754 |
| | Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients | Q47925996 |
| | Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. | Q50574786 |
| | Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. | Q50577144 |
| | Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group | Q72036552 |
| | Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients | Q81235545 |
| P433 | issue | 7-8 | |
| P304 | page(s) | 237-242 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | Vienna Clinical Weekly | Q15759796 |
| P1476 | title | Antiviral treatment of chronic hepatitis C in clinical routine | |
| P478 | volume | 122 | |